Loading patent…
AssigneeInnogenetics N.V.
InventorsGeert Maertens, Fons Bosman, Guy De Martynoff, Marie-Ange Buyse
Estimating the term…
The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.
An isolated E1 specific monoclonal antibody, said antibody specifically binding to at least one region within a domain spanning amino acids 192-383 of the hepatitis C virus polyprotein.
An isolated E1 specific monoclonal antibody which specifically binds to a region in the E1 domain spanning an amino acid segment selected from the group consisting of the segments spanning E1 amino acids 181 to 200, 193 to 212, 205 to 224, 208 to 227, 217 to 236, 229 to 248, 241 to 260, 253 to 272, 265 to 284, 289 to 308, 301 to 320, 313 to 332, 325 to 344, 337 to 356, 349 to 368, and 373 to 392.
Dependencies are inferred from the claim text.